The drug delivery systems market size has grown strongly in recent years. It will grow from $44.21 billion in 2025 to $47.54 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to reliance on conventional oral and injectable delivery, limited biologics formulations, growing hospital and clinical infrastructure, increasing chronic disease prevalence, rising r&d in pharmaceuticals.
The drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $62.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancement in polymer and lipid-based delivery systems, growth of personalized medicine, increasing use of inhalation and transmucosal delivery, rising adoption of homecare and self-administration devices, integration of digital monitoring and smart delivery technologies. Major trends in the forecast period include rising adoption of targeted and controlled drug release technologies, increasing development of biologics and advanced therapeutics, growth in homecare drug delivery solutions, expansion of minimally invasive and needle-free delivery systems, enhanced focus on patient compliance and safety.
The rising prevalence of respiratory disorders is expected to drive the growth of the drug delivery systems market in the coming years. Respiratory disorders are conditions that disrupt the normal function of the lungs and airways, causing breathing difficulties and reduced oxygen intake. The increase in these disorders is largely due to escalating air pollution, which exposes people to harmful airborne particles and gases that damage lung function and contribute to the onset and progression of respiratory diseases. Drug delivery systems play a vital role in the effective treatment and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis. These systems enable medications to be delivered directly to the lungs, improving therapeutic effectiveness while reducing systemic side effects. For example, in March 2025, the UK Health Security Agency - a government body in the UK - reported that tuberculosis cases in England rose by 13% in 2024, increasing from 4,850 cases in 2023 to 5,480 cases. Consequently, the growing prevalence of respiratory disorders is expected to propel the drug delivery systems market.
Key players in the drug delivery systems market are concentrating on developing advanced solutions like metal-free, multidose nasal spray pumps to enhance user comfort and ease of use. These metal-free, multidose nasal spray pumps are designed to administer multiple medication doses through the nasal route without incorporating any metal parts, ensuring safety and compatibility with various formulations. For example, in January 2023, Aptar Pharma, a pharmaceutical company based in the U.S., introduced the APF Futurity metal-free, multidose nasal spray pump. This device is specifically engineered for delivering nasal saline and similar over-the-counter products, with a strong emphasis on recyclability. It is Aptar Pharma’s first highly recyclable nasal spray pump, earning a Class AA certification from cyclos-HTP for European recycling standards. Constructed entirely from polyolefin materials and free from metal components or recycling contaminants, it facilitates easier recycling and enhances the quality of recycled materials. Incorporating Aptar Pharma’s Advanced Preservative Free technology, this metal-free pump provides precise and consistent dosing with smooth operation, maintaining ease of use and effectiveness.
In January 2024, Kindeva Drug Delivery, a U.S.-based contract development and manufacturing organization, acquired Summit Biosciences Inc. for an undisclosed sum. This acquisition expanded Kindeva’s drug delivery capabilities by adding a new platform. It enables the company to provide biopharmaceutical clients with a broader portfolio of advanced drug-device combination products, including those for pulmonary, injectable, transdermal, and nasal delivery. Summit Biosciences Inc. is a U.S.-based contract development and manufacturing firm specializing in intranasal drug delivery.
Major companies operating in the drug delivery systems market are Pfizer Inc., Johnson & Johnson, F. Hoffmann La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Tandem Diabetes Care, Pacira Biosciences Inc., Universal Stabilization Technologies Inc., Spectrum Pharmaceuticals Inc., West Pharmaceutical Services Inc., Catalent Inc., Recipharm AB.
North America was the largest region in the drug delivery system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug delivery systems market by increasing costs of imported polymers, lipids, and biologics used in manufacturing advanced delivery devices. Segments such as polymer-based systems, inhalers, and needle-free injectors are most affected, particularly in Asia-Pacific regions including China and India, major manufacturing hubs. This has led to higher production costs and delayed product launches. Positively, tariffs have encouraged local production, innovation in alternative materials, and investment in domestic manufacturing capabilities.
The drug delivery systems market research report is one of a series of new reports that provides drug delivery systems market statistics, including drug delivery systems industry global market size, regional shares, competitors with a drug delivery systems market share, detailed drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery systems industry. This drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug delivery systems are innovative technologies or methods developed to transport therapeutic agents within the body in a controlled and efficient way. These systems are designed to improve treatment effectiveness and safety by controlling the rate, timing, and location of drug release. They help maintain optimal drug concentrations at target sites, minimize side effects, and enhance patient adherence to prescribed treatments.
The primary categories of drug delivery systems include injection-based drug delivery systems, oral drug delivery systems, inhalation or pulmonary drug delivery systems, and transmucosal drug delivery systems. Injection-based drug delivery systems are medical devices used to administer drugs into the body via various injection routes, utilizing tools such as syringes, needles, or auto-injectors for precise and targeted delivery. These systems can be made from different material types, including polymer-based, lipid-based, inorganic, biologics-based, and hybrid drug delivery systems. They are used to treat conditions such as infectious diseases, cancer, eye disorders, urinary diseases, diabetes, central nervous system disorders, and more. Key end-users of these systems include hospitals, pharmaceutical companies, research institutions, homecare providers, and diagnostic laboratories.
The drug delivery systems market consists of sales of implantable devices, targeted delivery carriers, nanoparticle-based systems, and bio adhesive systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $62.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancement in polymer and lipid-based delivery systems, growth of personalized medicine, increasing use of inhalation and transmucosal delivery, rising adoption of homecare and self-administration devices, integration of digital monitoring and smart delivery technologies. Major trends in the forecast period include rising adoption of targeted and controlled drug release technologies, increasing development of biologics and advanced therapeutics, growth in homecare drug delivery solutions, expansion of minimally invasive and needle-free delivery systems, enhanced focus on patient compliance and safety.
The rising prevalence of respiratory disorders is expected to drive the growth of the drug delivery systems market in the coming years. Respiratory disorders are conditions that disrupt the normal function of the lungs and airways, causing breathing difficulties and reduced oxygen intake. The increase in these disorders is largely due to escalating air pollution, which exposes people to harmful airborne particles and gases that damage lung function and contribute to the onset and progression of respiratory diseases. Drug delivery systems play a vital role in the effective treatment and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis. These systems enable medications to be delivered directly to the lungs, improving therapeutic effectiveness while reducing systemic side effects. For example, in March 2025, the UK Health Security Agency - a government body in the UK - reported that tuberculosis cases in England rose by 13% in 2024, increasing from 4,850 cases in 2023 to 5,480 cases. Consequently, the growing prevalence of respiratory disorders is expected to propel the drug delivery systems market.
Key players in the drug delivery systems market are concentrating on developing advanced solutions like metal-free, multidose nasal spray pumps to enhance user comfort and ease of use. These metal-free, multidose nasal spray pumps are designed to administer multiple medication doses through the nasal route without incorporating any metal parts, ensuring safety and compatibility with various formulations. For example, in January 2023, Aptar Pharma, a pharmaceutical company based in the U.S., introduced the APF Futurity metal-free, multidose nasal spray pump. This device is specifically engineered for delivering nasal saline and similar over-the-counter products, with a strong emphasis on recyclability. It is Aptar Pharma’s first highly recyclable nasal spray pump, earning a Class AA certification from cyclos-HTP for European recycling standards. Constructed entirely from polyolefin materials and free from metal components or recycling contaminants, it facilitates easier recycling and enhances the quality of recycled materials. Incorporating Aptar Pharma’s Advanced Preservative Free technology, this metal-free pump provides precise and consistent dosing with smooth operation, maintaining ease of use and effectiveness.
In January 2024, Kindeva Drug Delivery, a U.S.-based contract development and manufacturing organization, acquired Summit Biosciences Inc. for an undisclosed sum. This acquisition expanded Kindeva’s drug delivery capabilities by adding a new platform. It enables the company to provide biopharmaceutical clients with a broader portfolio of advanced drug-device combination products, including those for pulmonary, injectable, transdermal, and nasal delivery. Summit Biosciences Inc. is a U.S.-based contract development and manufacturing firm specializing in intranasal drug delivery.
Major companies operating in the drug delivery systems market are Pfizer Inc., Johnson & Johnson, F. Hoffmann La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Tandem Diabetes Care, Pacira Biosciences Inc., Universal Stabilization Technologies Inc., Spectrum Pharmaceuticals Inc., West Pharmaceutical Services Inc., Catalent Inc., Recipharm AB.
North America was the largest region in the drug delivery system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug delivery systems market by increasing costs of imported polymers, lipids, and biologics used in manufacturing advanced delivery devices. Segments such as polymer-based systems, inhalers, and needle-free injectors are most affected, particularly in Asia-Pacific regions including China and India, major manufacturing hubs. This has led to higher production costs and delayed product launches. Positively, tariffs have encouraged local production, innovation in alternative materials, and investment in domestic manufacturing capabilities.
The drug delivery systems market research report is one of a series of new reports that provides drug delivery systems market statistics, including drug delivery systems industry global market size, regional shares, competitors with a drug delivery systems market share, detailed drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery systems industry. This drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug delivery systems are innovative technologies or methods developed to transport therapeutic agents within the body in a controlled and efficient way. These systems are designed to improve treatment effectiveness and safety by controlling the rate, timing, and location of drug release. They help maintain optimal drug concentrations at target sites, minimize side effects, and enhance patient adherence to prescribed treatments.
The primary categories of drug delivery systems include injection-based drug delivery systems, oral drug delivery systems, inhalation or pulmonary drug delivery systems, and transmucosal drug delivery systems. Injection-based drug delivery systems are medical devices used to administer drugs into the body via various injection routes, utilizing tools such as syringes, needles, or auto-injectors for precise and targeted delivery. These systems can be made from different material types, including polymer-based, lipid-based, inorganic, biologics-based, and hybrid drug delivery systems. They are used to treat conditions such as infectious diseases, cancer, eye disorders, urinary diseases, diabetes, central nervous system disorders, and more. Key end-users of these systems include hospitals, pharmaceutical companies, research institutions, homecare providers, and diagnostic laboratories.
The drug delivery systems market consists of sales of implantable devices, targeted delivery carriers, nanoparticle-based systems, and bio adhesive systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug Delivery Systems Market Characteristics
3. Drug Delivery Systems Market Supply Chain Analysis
4. Global Drug Delivery Systems Market Trends and Strategies
5. Drug Delivery Systems Market Analysis of End Use Industries
7. Global Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market
9. Drug Delivery Systems Market Segmentation
10. Drug Delivery Systems Market Regional and Country Analysis
11. Asia-Pacific Drug Delivery Systems Market
12. China Drug Delivery Systems Market
13. India Drug Delivery Systems Market
14. Japan Drug Delivery Systems Market
15. Australia Drug Delivery Systems Market
16. Indonesia Drug Delivery Systems Market
17. South Korea Drug Delivery Systems Market
18. Taiwan Drug Delivery Systems Market
19. South East Asia Drug Delivery Systems Market
20. Western Europe Drug Delivery Systems Market
21. UK Drug Delivery Systems Market
22. Germany Drug Delivery Systems Market
23. France Drug Delivery Systems Market
24. Italy Drug Delivery Systems Market
25. Spain Drug Delivery Systems Market
26. Eastern Europe Drug Delivery Systems Market
27. Russia Drug Delivery Systems Market
28. North America Drug Delivery Systems Market
29. USA Drug Delivery Systems Market
30. Canada Drug Delivery Systems Market
31. South America Drug Delivery Systems Market
32. Brazil Drug Delivery Systems Market
33. Middle East Drug Delivery Systems Market
34. Africa Drug Delivery Systems Market
36. Drug Delivery Systems Market Competitive Landscape and Company Profiles
37. Drug Delivery Systems Market Other Major and Innovative Companies
40. Drug Delivery Systems Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Drug Delivery Systems Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug delivery systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Injection-Based Drug Delivery System; Oral Drug Delivery System; Inhalation Or Pulmonary Drug Delivery System; Transmucosal Drug Delivery System2) By Material: Polymer-Based Drug Delivery Systems; Lipid-Based Drug Delivery Systems; Inorganic Drug Delivery Systems; Biologics-Based Drug Delivery Systems; Hybrid Drug Delivery Systems
3) By Application: Infectious Disease; Oncology; Ophthalmology; Urology; Diabetes; Central Nervous System; Other Applications
4) By End-User: Hospitals; Pharmaceutical Companies; Research Institutions; Homecare Settings; Diagnostic Laboratories
Subsegments:
1) By Injection-Based Drug Delivery System: Intravenous (IV); Intramuscular (IM); Subcutaneous (SC); Intradermal; Intrathecal; Depot Injections; Needle-Free Injectors2) By Oral Drug Delivery System: Tablets; Capsules; Solutions And Syrups; Suspensions; Powders And Granules; Modified Release Formulations
3) By Inhalation Or Pulmonary Drug Delivery System: Metered Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers; Soft Mist Inhalers; Nasal Sprays
4) By Transmucosal Drug Delivery System: Buccal Delivery; Sublingual Delivery; Rectal Delivery; Vaginal Delivery; Nasal Mucosal Delivery
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories Inc.; Novartis AG; GlaxoSmithKline PLC; Eli Lilly and Company; Amgen Inc.; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Tandem Diabetes Care; Pacira Biosciences Inc.; Universal Stabilization Technologies Inc.; Spectrum Pharmaceuticals Inc.; West Pharmaceutical Services Inc.; Catalent Inc.; Recipharm AB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug Delivery Systems market report include:- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Abbott Laboratories Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Amgen Inc.
- Becton Dickinson and Company
- Teva Pharmaceutical Industries Ltd.
- Tandem Diabetes Care
- Pacira Biosciences Inc.
- Universal Stabilization Technologies Inc.
- Spectrum Pharmaceuticals Inc.
- West Pharmaceutical Services Inc.
- Catalent Inc.
- Recipharm AB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 47.54 Billion |
| Forecasted Market Value ( USD | $ 62.89 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
